Slovenia · Delayed Price · Currency is EUR Krka, d. d. Earnings Call Transcripts
Fiscal Year 2026
-
Record H1 2026 sales and profitability were driven by prescription medicines, strong demand, and operational efficiency. Margins reached historic highs, with robust growth across most regions and segments. Outlook remains positive, targeting 5% annual sales growth and sustained high margins.
-
Q1 2026 saw record revenue and operating profit, with 8% sales growth and a 31% EBITDA margin. Growth was broad-based, led by Russia and Central Europe, while net profit was impacted by FX volatility. Outlook remains positive with continued investment and stable dividend policy.
Fiscal Year 2025
-
Record revenue and net profit were achieved in 2025, driven by strong growth across key markets and product launches. The outlook for 2026 projects continued sales and profit growth, with increased investment in capacity and innovation.